Europeanhhm

Magnus Medical Reveals Innovative SAINT Neuromodulation System for Commercial Introduction

Wednesday, May 01, 2024

Magnus Medical, Inc., a pioneering force in therapeutic neuromodulation, has announced the commercial release of the SAINT® neuromodulation system, a groundbreaking treatment for treatment-resistant major depressive disorder (MDD).

This innovative therapy alters brain circuitry to effectively address MDD by modulating activity in depression-related brain networks. With Breakthrough Device Designation and 510(k) clearance from the U.S. Food & Drug Administration (FDA), SAINT therapy has shown remarkable efficacy in alleviating severe depression symptoms in clinical settings.

"We are proud to be the inaugural site offering the breakthrough SAINT neuromodulation system for individuals battling depression," said Dr. Laura B. Dunn, Chair of the Department of Psychiatry at the University of Arkansas for Medical Sciences. "I firmly believe this innovative approach will revolutionize patients' lives."

Utilizing structural and functional MRI scans, SAINT therapy employs a proprietary algorithm to precisely target neurostimulation in MDD patients. The treatment unfolds over an expedited five-day schedule, tailoring stimulation to each individual's unique brain connectivity.

Magnus Medical, expressed excitement over the system's launch. "This marks a pivotal moment in the depression treatment landscape," he stated. "SAINT therapy offers rapid relief to those who have long suffered, potentially reshaping how we approach major depression treatment."

Additionally, Magnus Medical has secured New Technology Add-on Payment (NTAP) approval from the Centers for Medicare & Medicaid Services (CMS) for SAINT therapy, marking a significant milestone in interventional psychiatry reimbursement.

Furthermore, the American Medical Association (AMA) has introduced new Category III Current Procedural Terminology (CPT) codes for accelerated iTBS for depression, encompassing the SAINT system. Magnus Medical is actively pursuing comprehensive insurance coverage for SAINT therapy, anticipating growth in coverage over the coming years.


 

Source: businesswire.com

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024